Successfully Manufacturing and Marketing Small Molecule and Biologic Drugs for Gastrointestinal Problems

Materials Studio


Biologics development for the gut is on the rise as we learn more about these poorly understood disorders. Image Source: Flickr User: litldesign

As it turns out, a healthy gut is something people will pay a lot of money for. The global market for gastrointestinal disorder therapeutics and diagnostics reached $49.6 billion in 2015 and is expected to grow to $63.8 billion in 2021.1 There has been a rise in reported cases of issues such as Celiac’s disesase, irritable bowel, inflammatory bowel disease (IBD) and Crohn’s, which necessitates the need for better and more varied medication.2

There are a number of successful medications out there, but there is still plenty of room within that realm for improvement. Additionally, all the medications that are currently more successful need to be marketed better, as many of those suffering with these types of issues have not heard of many of them. As modern lab technology continues to evolve, closing the gaps in the market will be made easier, giving much needed relief to the masses.

Current Concerns in Treatment

Many gut disorders remain poorly understood with few widely successful treatment option. For example, some people with Crohn’s disease may go into remission for years, only to have the illness resurface with renewed vengeance. This is because there are a number of issues that are currently faced by patients and drug developers:

  • Variability Between Patients: Treatment for Crohn’s disease can vary between patients, even from two patients from the same family. What works on the parent may have little to no effect on the child. Diseases of the gut are complex and widely variable, even between genetically similar people. There’s a lot of room here for researchers to employ innovative lab technology to track and identify common themes, which may extend well beyond the GI tract. Additionally, it may give researchers the data they need to take more of a “top-down” approach to treating these disorders, treating from a more holistic perspective rather than symptom by symptom.
  • Wide Variety of Symptoms: There are a number of different approaches that researchers and practitioners take to dealing with the gut. This generally hinges on the use of different anti-inflammatories or antibiotics; however, there is vast room for improvement in symptom treatment. Hopefully, tracking symptom trends by utilizing computer modelling technology, researchers will be able to take a more holistic approach.
  • Interactions with Other Systems Within the Body: A hot topic in the medical community over the past few years has been the microbiomes found within the human body, specifically those along the gut lining. Many medications have been implicated as having adverse effects on the gut microbiome leading to catastrophic symptoms further down the line. As researchers move forward in this realm, they will need to model biologics and small molecules in order to account for the bacterial species that need to exist in the gut.

Moving Candidates to Market

As biologics and small molecule medication companies look to take their candidate therapeutics to market, many patients and practitioners will benefit from knowing exactly what symptoms in which diseases these medications most successfully treat. To be able to do this more targeted research and marketing, labs will need to invest in modern lab software that will guide them through the entire process, act as a hub for information from bench to clinic and allow for collaboration between labs and facilities.

With BIOVIA Materials Studio this is all possible. It allows for researchers to design and test hypotheses regarding specific outcomes in specific disorders and allows them to track it from bench to bedside. Comprehensive models can be created to allow researchers to better predict what will work taking different factors, such as the gut microbiome, into account saving both time and money. Materials studio can help investigators to eliminate repetitive testing by automating modelling tasks. Better gut therapeutics are on the horizon and Materials Studio can help get you there. Please contact us today to learn more about how our software options can support the efforts of your lab.



  1.   “Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets,” September 2016,


  2. “Dramatic increase in hospitalization of US children with inflammatory bowel disease,” June 25, 2013,